Tumors of the peripheral nervous system include neuroblastomas, pheochromocytomas, and neuroepitheliomas. Neuroblastomas and pheochromocytomas are adrenergic in origin and share certain genetic features, whereas neuroepitheliomas are thought to be cholinergic and are characterized by distinct genetic features. Neuroblastomas are characterized by deletion of the short arm of chromosome 1 (lp), amplification of the MYCN proto-oncogene, and hyperdiploidy in subsets of tumors. All three of these genetic features have prognostic value in subsets of patients. Allelic loss of 14q also occurs with increased frequency, but the prognostic importance of this abnormality is not known yet. Pheochromocytomas have not been studied as extensively, but allelic loss for lp appears to be a frequent change, and no clear examples of oncogene activation have been identified to date. Neuroepitheliomas are characterized by translocation between chromosomes 11 and 22. Although they have a characteristic pattern of proto-oncogene expression, it is not clear that any of these oncogenes are activated specifically, and no sites of allelic loss have been identified to date. Thus, cytogenetic and molecular analysis of neuroblastomas, pheochromocytomas, and neuroepitheliomas are useful in distinguishing them from each other and from other tumors in selected cases. Furthermore, certain genetic markers are useful in predicting clinical behavior, especially for neuroblastoma.
oncogene, deletion of the short arm of chromosome 1, and hyperdiploid or near-triploid tumor cell DNA content. In addition, other abnormalities have been identified more recently whose clinical significance is not known as yet. These observations have contributed to our understanding of tumor heterogeneity, malignant transformation and progression. In this section, the clinical and biological significance of these genetic changes will be reviewed.
Cytogenetic analysis and assessment of DNA content
Neuroblastomas are characterized cytogenetically by deletion of the short arm of chromosome 1 (lp), double minute chromatin bodies (drains) and homogeneously staining regions (HSRs) [11] [12] [13] . The former is thought to be the site of a suppressor gene that is lost or inactivated in neuroblastomas, whereas the latter two abnormalities are cytogenetic manifestations of gene amplification. The molecular and clinical significance of these abnormalities is discussed in detail below. No other cytogenetic abnormality has emerged as yet that is characteristic of neuroblastomas. The majority of neuroblastomas have a near-diploid chromosome number or DNA content, as detected by flow cytometric analysis, whereas some are clearly hyperdiploid, near triploid or even tetraploid.
Flow cytometric analysis of the DNA content of human neuroblastoma cells was first reported by Look and colleagues [14] in a series of infants. In this analysis, abnormally high DNA content was associated with lower stages of tumor and a response to initial chemotherapy, whereas those with a 'normal' DNA content were likely to have advanced stages of tumor (especially stage 4) and a poor response to this chemotherapy. This latter group of tumors likely had subtle genetic abnormalities that were not detectable by flow cytometry, such as dmins or chromosome 1 deletions. Subsequent studies have confirmed the prognostic importance of hyperdiploidy by flow cytometric measurement of DNA content [15] [16] [17] [18] [19] [20] [21] [22] , or by karyotype analysis [23] [24] [25] [26] [27] , although the utility of this marker may be limited to patients less than one or two years of age [19] .
Loss of heterozygosity and mapping of putative suppressor genes
Deletion of the short arm of chromosome 1 has emerged as the most characteristic cytogenetic abnormality in primary human neuroblastomas and tumor-derived cell lines [1, 11-13, 28, 29] . The deletions of chromosome 1 usually lead to partial lp monosomy, and the region most commonly deleted in these tumors is between lp32 and lpter [1, 2, 12] . This deletion is thought to represent the loss of a putative neuroblastoma suppressor gene. Unfortunately, no chromosome deletion syndrome has been identified as yet that predisposes to the development of neuroblastoma [1, 3] . In order to define the region that is deleted more precisely, we undertook a molecular approach to define the region of consistent deletion.
We used a panel of chromosome-l-specific DNA probes that identify restriction fragment length polymorphisms (RFLPs) along the short and long arms of chromosome i to assess chromosome deletion or somatic loss of heterozygosity (LOH). By comparing the pattern seen in normal DNA of heterozygous patients with that obtained in tumor DNA from the same patient, we could assess LOH, which is the molecular equivalent of deletion. Based on our analysis of a panel of normal and tumor DNA pairs from individual patients [30] , the common region of LOH between lp36.1 and proximal lp36.3 ( Fig. 1) . Similar results have been obtained independently by other investigators [31] . We postulate that loss or inactivation of a putative neuroblastoma suppressor gene at this site is critical for the development or progression of neuroblastoma. Furthermore, lp deletion or LOH may be an adverse prognostic marker (see below).
Mutation in the critical lp36 locus on one chromosome, followed by deletion of the same region on the homologous chromosome (as manifested by LOH) may be an important mechanism in the malignant transformation or progression of some or all human neuroblastomas. Indeed, there is recent evidence that the introduction of lp into a neuroblastoma cell line caused neural differentiation followed by cessation of cell growth and ultimately cell death [32] . This provides functional evidence to support the structural evidence for a neuroblastoma suppressor gene on the short arm of chromosome 1.
There is recent evidence that LOH for the long arm of chromosome 14 also occurs with increased frequency in neuroblastomas [33] . In this report, LOH for chromosome 14 was found in 6 of 12 informative cases, whereas LOH for chromosome lp was found in 2 of 9 cases, and one case had LOH for both regions. In addition, they found LOH for chromosome 13q in 2 of 11 cases. Although the exact frequency and significance of these abnormalities is not yet clear, the finding of LOH on other chromosomes besides lp provides further evidence for genetic heterogeneity in this tumor.
Oncogene activation
A substantial number of neuroblastomas have either extrachromosomal double minute chromatin bodies (dmins) or chromosomally integrated homogeneously-staining regions (HSRs) [1, 12] We determined that N-myc was amplified from 3-to 300-fold in a substantial number of primary neuroblastomas from untreated patients [38] . Nrnyc amplification was highly correlated with advanced stages of disease, rapid progression and a poor outcome [38] [39] [40] . These studies have been extended to over 1,200 patients with neuroblastoma enrolled in protocols of the Children's Cancer Study Group (CCSG) and the Pediatric Oncology Group (POG) [1, 2, 29] . Examples of N-myc amplification seen in some of the primary tumors are shown in Fig. 2 . The strong association between N-myc amplification and advanced stages of disease seen in our earlier studies were borne out by the larger study (Table 1) . However, a minority of patients with more localized disease have tumors with N-myc amplification. Tumors with amplification are associated with more rapid progression and a worse outcome than their non-amplified counterparts, and this was especially true for patients with lower stages of disease [1, 2, 29] . This association between N-myc amplification and a poor prognosis is supported by studies from Japan and Europe [22, [41] [42] [43] . 2.0 kb--
2.0 kb Our recent studies showed a very strong correlation between N-myc amplification and chromosome lp LOH, indicating that lp LOH was common in patients with amplification [30] . Both Nmyc amplification [2, 22, [38] [39] [40] [41] 43] , and deletion of chromosome lp (as detected by cytogenetic analysis) [24-27, 49], appear strongly correlated with a poor clinical outcome and with each other, but it is not yet clear if they are independent prognostic variables. Nevertheless, they appear to characterize a genetically distinct subset of very aggressive neuroblastomas. Our data showing the consistency of N-myc copy number over time [44] would suggest that N-myc amplification is an intrinsic biologic property of a subset of tumors, so it must occur relatively early in these cases. Since cases with N-myc amplification represent a subset of patients with chromosome lp deletion, we suspect that the lp deletion may precede the development of amplification.
We have sought evidence for amplification or overexpression of a number of other oncogenes in a panel of neuroblastoma cell lines and primary tumors, but none was found [1] . Although N-ras was first identified as the transforming gene of a human neuroblastoma cell line [50, 51] , subsequent studies of primary neuroblastomas by ourselves and others [52] [53] [54] indicate that ras activation by mutation of codons 12, 13, 59 or 61 is rare. Recent studies of H-ras and c-src expression in neuroblastomas suggest that higher levels of expression were associated differentiated histology and with a good prognosis [55, 56] . Thus, in the patients whose tumors lack N-myc amplification, patterns of oncogene expression may identify a subset with a more favorable outcome.
Recent studies have compared tumor cell ploidy and N-myc amplification in neuroblastomas [19] [20] [21] [22] . There was a general correlation between Nmyc amplification and near-diploidy, although the correlation was not absolute. It appears that each is the predominant prognostic factor for a given subset of patients. The majority of infants with localized disease had hyperdiploid tumors, and hyper-325 diploidy identified a subset of infants with more advanced disease who had a good prognosis. On the other hand, while N-myc amplification does not identify all patients who are destined to fail, it does identify a substantial number of infants, as well as older patients with nonmetastatic disease, who have a very poor prognosis. Thus, analysis of Nmyc copy number, as well as tumor cell ploidy, provides complementary genetic information that is extremely useful in predicting response to therapy and outcome.
Summary
Neuroblastomas are heterogeneous in terms of their genotype and their clinical behavior. Recent studies suggest that these two features are related, and that the genotype frequently is predictive of response to treatment or the outcome of the patient. The genetic abnormalities which are characteristic of certain neuroblastomas include: 1) loss of heterozygosity (LOH) for the short arm of chromosome 1, including band lp36; 2) amplification of MYCN (N-myc) proto-oncogenc; and 3) hyperdiploidy, or near-triploidy determined by flow cytometry or karyotype. Hyperdiploidy is associated with lower stages of disease and with a favorable outcome in infants. However, LOH for chromosome 1 (band p36) and N-myc amplification are more common in patients over 1 year of age with advanced stages of disease.
Patterns are emerging, based on cytogenetic, molecular, and flow cytometric analysis, which suggest that neuroblastomas may be assigned to three genetically distinct groups ( Table 2 ). The first comprises those with hyperdiploid or triploid modal karyotypes (or compatible DNA content by flow cytometry). LOH of lp and N-myc amplification are rarely seen. These patients are more likely to be infants with low stages of disease (stages 1, 2, or 4-S by the International Neuroblastoma Staging System) [57] , and they generally have a very favorable prognosis. The second group consists of tumors that generally have a near-diploid or tetraploid modal chromosome number of DNA content. These tumors lack lp L O H and N-myc amplifica- 4) . In contrast to the second group, they respond to treatment only transiently, if at all, before they have rapid tumor progression and die within six to twelve months or so. It remains to be determined if tumors in one group ever evolve or 'progress' into a less unfavorable group, but current evidence would suggest that they are distinct genetically. Thus, genetic analysis of neuroblastoma cells provides prognostic information beyond that provided by age and stage alone. Consideration of the genotype of neuroblastomas can direct the choice of treatment more appropriately.
Pheochromocytomas
Pheochromocytoma is a rare tumor which is derived from chromaffin cells [58] . This tumor generally occurs in the adrenal medulla, but it may also arise in the organ of Zuckerkandl or in the retroperitoneal area. About 20% of pheochromocytomas occur in the pediatric age group, and about one third have multiple primary tumors. Since this tumor excretes urinary catecholamines, some patients present with hypertension due to excessive catecholamine secretion. Since urinary catecholamine metabolites are almost always increased, the tumor must be distinguished from neuroblastoma by clinical, radiographic and histological features [59] . Although the majority of pheochromocytomas are benign, some are locally invasive and metastatic, and the distinction between malignant and benign tumors is based on clinical behavior. Pheochromocytomas can occur sporadically or as part of several genetic syndromes, such as multiple endocrine neoplasia (MEN) type 2A, MEN-2B, neurofibromatosis type 1 (NF-1) and von Hippel Landau (vHL). Interestingly, the predisposition locus for MEN-2A and -2B has been mapped to the pericentromeric region of chromosome 10 [60] [61] [62] , whereas NF-1 has been mapped to chromosome 17q [63] and vHL has been mapped to 3p [64] . This suggests that predisposition to develop this tumor is heterogeneous genetically. Thus, either there are several different genetic pathways to develop pheochromocytoma, or else what appears to be the same tumor histologically may actually be several different tumors genetically. Frequently it is difficult to predict the clinical behavior of these tumors based on the histologic appearance alone. A recent study demonstrated a correlation between expression of neuropeptide Y benign clinical behavior of pheochromocytomas [65] . However, this association was not confirmed in another report [66] . A better understanding of the genetic features of these different forms of neuroendocrine neoplasia may provide useful markers to predict clinical behavior.
Cytogenetic analysis and assessment of DNA content
There is very limited information about genetic features sporadic or hereditary pheochromocytomas. This is due in part to its infrequency, less malignant behavior, and its low mitotic rate. In one study of three pheochromocytomas in patients with vHL, one had a normal karyotype, one had trisomy 7, and a third had several clones, one of which had abnormalities of chromosome 3p [67] . In another report there was partial monosomy for chromosome 22 [68] . However, no consistent karyotypic abnormalities have been identified to date, and there have not been any flow cytometric studies of the DNA content of pheochromocytomas.
Loss of heterozygosity and mapping of putative suppressor genes
In patients with hereditary retinoblastoma, all of the normal (or constitutional) cells of the body are heterozygous for the retinoblastoma locus on the long arm of chromosome 13. That is, they have one copy of a mutated gene, and one copy of the normal gene. The normal gene is expressed in a dominant fashion, so these cells do not exhibit malignant features. The retinoblastomas which develop in these patients, on the other hand, are homozygous for a mutated retinoblastoma gene. That is, they have lost the normal, wild-type gene, which allows expression of the retinoblastoma phenotype and formation of a tumor. However, loss of heterozygosity (LOH) at the predisposing gene locus has not been found in tumors of the MEN-2A syndrome. Three recent reports noted allelic loss on chromosome 10 in only 5% of cases (4 of 84 informative tumors) [69] [70] [71] . Therefore, malignant transformation in MEN-2A probably is caused by some mechanism other than homozygous loss or mutation of the predisposition locus.
Several studies using polymorphic probes for the short arm of chromosome 1 have noted LOH involving lp in about half the cases studied [72] [73] [74] [75] [76] [77] . In cases in which it was examined, these deletions were not noted in the constitutional (normal) DNA of the patients, indicating that the deletion does not reflect the site of the inherited mutation. LOH has been noted on other chromosomes, including 3p, llp, 17p and chromosome 22q, but LOH for lp has been the most consistent finding to date in the studies of allelic loss in these tumors [72] [73] [74] [75] [76] [77] . This suggests that an important suppressor gene resides on this chromosomal arm, and its loss or inactivation plays a role in the development or progression of pheochromocytomas, at least in a substantial subset of patients. It is possible that allelic loss 327 occurs with increased frequency on some other chromosomal arm or arms, since most studies have involved small numbers of cases and/or polymorphic probes for a limited number of chromosomal arms. Nevertheless, lp LOH has been seen frequently in every study in which it was examined.
Oncogene activation
One group used in situ hybridization of paraffinimbedded tissue sections and noted high levels of expression of the proto-oncogene N-myc in six of 21 MTC's analyzed [78] . Steady-state expression of the c-myc proto-oncogene also has been observed in one pheochromocytoma from a patient with the MEN-2A syndrome. Finally, a recent study demonstrated expression (without gene amplification or rearrangement) of c-myc and c-fos in six pheochromocytomas, suggesting that these cells are in a state of growth stimulation [79] . These studies suggest that increased expression of N-myc, c-myc, c-los, and possibly other oncogenes may be characteristic at least of some pheochromocytomas. Whether or not this increased expression represents activation of these oncogenes, or merely reflects their active state of growth, remains to be determined.
The ras family of oncogenes (N-ras, H-ras, Kras) has been implicated in the development of a variety of human tumors. Given the prevalence of ras mutations in human cancers, and the association of ras mutations with early changes and lower grade malignancies, it was reasonable to suspect that ras mutations might occur in pheochromocytomas and MTC's. Two recent studies have examined the ras genes of pheochromocytomas and medullary thyroid cancers for mutations of codons 12, 13, 59, 60 and 61 [54, 71] . Both studies concluded that mutational activation of ras genes rarely if ever occurs in these tumors.
Insulin-like growth factor II (IGF-II) and its receptor (IGFR). IGF-I and IGF-II are polypeptide hormones that are structurally and functionally similar to insulin [80] . There is some evidence that IGF-II is expressed at high levels in fetal tissues, and it stimulates growth of certain cells in vitro.
The growth-stimulating activity of IGF-I and IGF-II is mediated by the IGF receptor (IGFR), which is a heterotetrameric protein that is similar to the insulin receptor [81] . Increased levels of IGF-II (but not IGF-I) have been demonstrated in fetal adrenal medulla, compared to the adult adrenal [82] . Interestingly, increased levels of IGF-II were detected in 11/11 pheochromocytomas from two studies [83, 84] . A neuroblastoma cell line has been described which demonstrates autonomous growth in serum-free medium which is mediated by IGF-II [84] . Indeed, some other neuroblastoma cell lines show increased growth rates in response to IGF-II in the medium [85] . These results suggest that the IGF-II/IGFR pathway may represent an autocrine or paracrine pathway of growth stimulation in neuroblastomas and possibly pheochromocytomas.
Summary
Pheochromocytomas may occur sporadically or in a variety of genetic backgrounds. The most characteristic genetic feature of these tumors is allelic loss for lp, whereas other sites of allelic loss may occur as well. There have been several preliminary studies to detect activation of selected oncogenes and growth factors by amplification, gene rearrangement, overexpression, or base-pair mutation, but there are no unequivocal examples of genetic alterations leading to activation of a particular oncogene in these tumors. It is reasonable to examine more tumors for patterns of allelic loss or oncogene activation, but no particular oncogene or mechanism of activation has been identified so far that is characteristic of these tumors.
Neuroepitheliomas
Peripheral neuroepithelioma (also known as primitive neuroectodermal tumor or PNET) is an uncommon malignant tumor of the peripheral nervous system [86] [87] [88] [89] . While this tumor can resemble neuroblastoma histologically, there are distinguishing clinical and biological features (Table 3 ) [90, 91] . These tumors tend to occur in older patients and are more commonly arise in the chest wall or extremities from peripheral nerves. Biologically these tumors are characterized by a specific translocation between chromosomes 11 and 22 (see below), and they have a cholinergic neurotransmitter enzyme phenotype. Recent evidence from chromosome analysis and oncogene expression pattern suggests that they may be related closely to Ewing sarcomas.
Cytogenetic analysis and assessment of DNA content
The majority of neuroepitheliomas that have been karyotyped have a reciprocal translocation involving chromosomes 11 and 22: t(ll;22)(q24;q12) [92, 93] . However, they do not have lp deletions or the cytogenetic manifestations of gene amplification (dmins, HSRs), which are characteristic of many neuroblastomas. Thus, the cytogenetic features serve to distinguish neuroepitheliomas from neu- 
Oncogene expression
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* Modified from previous publication [91] .
roblastomas (Table 3 ). There have not been any reports of analysis of tumor cell DNA content, but the majority of neuroepitheliomas have karyotypes that are pseudodiploid or hyperdiploid (47-53 chromosomes) [92, 93] .
Loss of heterozygosity and mapping of putative suppressor genes
There have been no studies documenting consistent deletions of L O H of any chromosomal regions. It is possible that there is a suppressor gene whose expression is altered by the translocation between chromosomes 11 and 22. However, it seems more likely that this rearrangement results in activation of an oncogene, as is seen in most translocation breakpoints that have been cloned in leukemias. There have been very few molecular studies of neuroepitheliomas other than those focused on the 11;12 translocation. Thus, it is likely that more information will be obtained concerning L O H and putative suppressor gene loci once additional tumors are studied.
Oncogene ac~va6on
There have been several studies of oncogene expression in neuroepitheliomas. In one study, patterns of oncogene expression served to distinguish this tumor from neuroblastomas, which it resembles histologically [90] . In another study, the pattern of oncogene expression of neuroepitheliomas and Ewing sarcoma, a tumor of bone, were indistinguishable [94] . Both had moderate expression of c-myc, and no expression of N-myc. In addition, both had moderate expression of H L A class I antigens, whereas neuroblastomas have very low H L A antigen expression, low or absent c-myc expression, and moderate to high N-myc expression. Even though the c-etsl gene maps near the breakpoint on chromosome 11, and c-sis maps near the breakpoint on chromosome 22, neither appears to be activated by the 11;12 translocation in neuroepitheliomas or Ewing sarcomas [95] [96] [97] [98] . Thus, despite a characteristic pattern of oncogene expres-329 sion in these tumors, no oncogene has been shown to be activated specifically.
Summary
Neuroepitheliomas resemble neuroblastomas histologically, although they are readily distinguishable on the basis of clinical and biological features. However, neuroepitheliomas do share a number of features with Ewing sarcomas, such as a characteristic 11;22 translocation and similar patterns of expression of oncogenes, H L A antigens and other histochemical markers. Although this translocation was identified over 7 years ago, the breakpoint has not yet been cloned, and no one had identified as yet a specific suppressor gene that is inactivated or oncogene that is activated. There is still a great deal to be learned about this intriguing group of tumors.
Conclusions
Neuroblastoma, pheochromocytoma and neuroepithelioma are neuroectodermal tumors of the peripheral nervous system. Although the former two share a similar genetic lesion -deletion of lp -it is not clear if the same gene or locus is involved in the pathogenesis of both diseases. Indeed, given the rather large deletions of lp in most pheochromocytomas, it is possible that a more proximal locus is involved, or possibly two distinct loci on lp. Furthermore, these two tumors have very different clinical behaviors. Neuroblastomas are common in infants and frequently are metastatic at diagnosis, whereas pheochromocytomas are more common in adults, and they have a much more benign clinical behavior. Neuroepitheliomas resemble neuroblastomas histologically, but they can be distinguished readily 
